IHC Expansion Cell Marque, now part of MilliporeSigma, is expanding its portfolio with a new line of Microscopy products and a focus on primary antibodies for in vitro diagnostics, presenting cross-sell opportunities between antibodies and histology/imaging products.

New Antibody Launches Recent launches of Uroplakin II and H3 K27M indicate active product development and a potential for bundled IHC solutions targeting urothelial pathology and diffuse midline gliomas in diagnostics laboratories.

Milp Sigma Synergy As a part of MilliporeSigma, Cell Marque can leverage Merck KGaA distribution, regulatory, and quality capabilities to pursue quality-centric labs seeking validated antibodies and robust microscopy reagents, enabling accelerated procurement cycles.

Mid-Sized Focus With 51-200 employees and revenue in the 25-50 million range, the company targets mid-sized labs that may require scalable IHC antibody panels and microscopy consumables, offering a clear route for recurring orders through standardization programs.

Competitive Positioning Product breadth in histology, hematology, cytology, and bacteriology paired with a high-quality microscopy line positions Cell Marque as a comprehensive lab solution provider, suitable for labs evaluating single-vendor IHC and imaging workflows.